These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 33008427)

  • 1. The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor.
    Hinsley S; Walker K; Sherratt D; Bailey L; Reed S; Flanagan L; McKee S; Brudenell Straw F; Dawkins B; Meads D; Auner HW; Kaiser MF; Cook M; Brown S; Cook G;
    Trials; 2020 Oct; 21(1):826. PubMed ID: 33008427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results.
    Auner HW; Brown SR; Walker K; Kendall J; Dawkins B; Meads D; Morgan GJ; Kaiser MF; Cook M; Roberts S; Parrish C; Cook G
    Blood Cancer J; 2022 Apr; 12(4):52. PubMed ID: 35365598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
    Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
    J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.
    Lee HC; Ramasamy K; Macro M; Davies FE; Abonour R; van Rhee F; Hungria VTM; Puig N; Ren K; Silar J; Enwemadu V; Cherepanov D; Leleu X
    Eur J Haematol; 2024 Aug; 113(2):190-200. PubMed ID: 38654611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial.
    Striha A; Ashcroft AJ; Hockaday A; Cairns DA; Boardman K; Jacques G; Williams C; Snowden JA; Garg M; Cavenagh J; Yong K; Drayson MT; Owen R; Cook M; Cook G
    Trials; 2018 Mar; 19(1):169. PubMed ID: 29514706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
    Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
    Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
    Dimopoulos MA; Schjesvold F; Doronin V; Vinogradova O; Quach H; Leleu X; Montes YG; Ramasamy K; Pompa A; Levin MD; Lee C; Mellqvist UH; Fenk R; Demarquette H; Sati H; Vorog A; Labotka R; Du J; Darif M; Kumar S
    Blood Cancer J; 2022 Jan; 12(1):9. PubMed ID: 35075109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
    Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
    Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
    Hájek R; Minařík J; Straub J; Pour L; Jungova A; Berdeja JG; Boccadoro M; Brozova L; Spencer A; van Rhee F; Vela-Ojeda J; Thompson MA; Abonour R; Chari A; Cook G; Costello CL; Davies FE; Hungria VT; Lee HC; Leleu X; Puig N; Rifkin RM; Terpos E; Usmani SZ; Weisel KC; Zonder JA; Bařinová M; Kuhn M; Šilar J; Čápková L; Galvez K; Lu J; Elliott J; Stull DM; Ren K; Maisnar V
    Future Oncol; 2021 Jul; 17(19):2499-2512. PubMed ID: 33769076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).
    Voorhees PM; Suman VJ; Tuchman SA; Laubach JP; Hassoun H; Efebera YA; Mulkey F; Bova-Solem M; Santo K; Carlisle D; McCarthy PL; Richardson PG
    Am J Hematol; 2021 Dec; 96(12):1595-1603. PubMed ID: 34559902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma.
    Iida S; Izumi T; Komeno T; Terui Y; Chou T; Ikeda T; Berg D; Fukunaga S; Sugiura K; Sasaki M
    Int J Clin Oncol; 2022 Jan; 27(1):224-233. PubMed ID: 34599726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.
    Terpos E; Ramasamy K; Maouche N; Minarik J; Ntanasis-Stathopoulos I; Katodritou E; Jenner MW; Plonkova H; Gavriatopoulou M; Vallance GD; Pika T; Kotsopoulou M; Kothari J; Jelinek T; Kastritis E; Aitchison R; Dimopoulos MA; Zomas A; Hajek R
    Ann Hematol; 2020 May; 99(5):1049-1061. PubMed ID: 32236735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
    Moreau P; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Simpson DR; Gimsing P; Palumbo A; Garderet L; Cavo M; Kumar S; Touzeau C; Buadi FK; Laubach JP; Berg DT; Lin J; Di Bacco A; Hui AM; van de Velde H; Richardson PG;
    N Engl J Med; 2016 Apr; 374(17):1621-34. PubMed ID: 27119237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma.
    Hari P; Lin HM; Zhu Y; Berg D; Richardson PG; Moreau P
    J Med Econ; 2018 Aug; 21(8):793-798. PubMed ID: 29741409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.
    Li J; Bao L; Xia Z; Wang S; Zhou X; Ding K; Zhang W; Yang W; Li B; Fu C; Chen B; Hua L; Wang L; Luo J; Yang Y; Xu T; Wang W; Huang Y; Wu G; Liu P
    Ann Hematol; 2020 Nov; 99(11):2589-2598. PubMed ID: 32892275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone
    Mateos MV; Masszi T; Grzasko N; Hansson M; Sandhu I; Pour L; Viterbo L; Jackson SR; Stoppa AM; Gimsing P; Hamadani M; Borsaru G; Berg D; Lin J; Di Bacco A; van de Velde H; Richardson PG; Moreau P
    Haematologica; 2017 Oct; 102(10):1767-1775. PubMed ID: 28751562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma.
    Ludwig H; Poenisch W; Knop S; Egle A; Schreder M; Lechner D; Hajek R; Gunsilius E; Krenosz KJ; Petzer A; Weisel K; Niederwieser D; Einsele H; Willenbacher W; Melchardt T; Greil R; Zojer N
    Br J Cancer; 2019 Oct; 121(9):751-757. PubMed ID: 31558804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and Safety of Ixazomib-Lenalidomide-Dexamethasone Therapy for Relapsed and Refractory Multiple Myeloma].
    Takakuwa T; Araki T; Miura A; Fujitani Y; Takeoka Y; Ohta K; Yamamura R
    Gan To Kagaku Ryoho; 2019 Jun; 46(6):1043-1047. PubMed ID: 31273172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
    Armoiry X; Connock M; Tsertsvadze A; Cummins E; Melendez-Torres GJ; Royle P; Clarke A
    Pharmacoeconomics; 2018 Sep; 36(9):1073-1081. PubMed ID: 29582405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The MODIFY Study Protocol: An Open-Label, Single-Arm, Multicenter, Prospective Pragmatic Study of Ixazomib-Based Triple-Drug Therapy in Chinese Patients with Multiple Myeloma.
    Chen W; Liu A; Li L
    Adv Ther; 2023 Feb; 40(2):705-717. PubMed ID: 36463561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.